Robert L. Coleman, MD | Authors

Articles

Evaluating Next Steps for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 21, 2020

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.

Rationale for Chemotherapy Plus Veliparib in Frontline Treatment of Ovarian Cancers

October 08, 2019

Robert L. Coleman, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, explains the rationale for the VELIA trial of veliparib with frontline chemotherapy and maintenance in patients with high-grade ovarian cancer.

Dr. Coleman Discusses the Toxicities Associated With Rucaparib in Patients With Ovarian Cancer

August 18, 2015

Robert L. Coleman, MD, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the toxicities associated with rucaparib in patients with ovarian cancer.